ClinicalTrials.gg
RecruitingNCT07476339REINITIATEUpdated Nov 16, 2026

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

A Phase 4 interventional study of Bictegravir, emtricitabine, and tenofovir alafenamide in HIV -1 Infection, HIV (Human Immunodeficiency Virus) and HIV, sponsored by CAN Community Health. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by CAN Community Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 16, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person's health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, it can be difficult for people who miss doses to get back on treatment right away. There are often several steps and medical appointments required before restarting, such as waiting for lab results or reviewing medical history, which can cause further delays. These additional steps can make it even harder for people to re-engage and may discourage them from returning to care.

The REINITIATE study is designed for people living with HIV who have not taken any antiretroviral medications for at least the last 12 weeks. The study will offer participants a way to restart their HIV therapy quickly, by beginning treatment with B/F/TAF on the same day that they return to care. B/F/TAF is a widely used, once-daily HIV regimen, and is recommended in national treatment guidelines.

Researchers want to find out if this rapid restart approach is safe and effective, and whether it helps people regain control of HIV and remain in care. The study will also examine how many participants are able to keep the virus at a low level (viral suppression), stay engaged in their HIV care, and tolerate the medication after rapidly restarting treatment. In addition, the study will include interviews with some participants, to gain a better understanding of why they stopped taking their medications and what supported their return to treatment. These insights could help healthcare teams develop better ways to support people living with HIV in the future.

Read the detailed description

This prospective, multicenter, open-label, single-arm, Phase 4, interventional study aims to evaluate rapid antiretroviral therapy (ART) restart with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in participants' routine clinical environments, facilitating data collection on treatment effectiveness and safety following same-day ART reinitiation amongst treatment-experienced people with HIV (PWH) who have had a treatment interruption of at least 12 weeks. This study will also characterize reasons for ART interruption and reinitiation.

B/F/TAF, a three-drug combination of bictegravir (B; a second-generation HIV-1 integrase strand transfer inhibitor [INSTI]), and emtricitabine (F) and tenofovir alafenamide (TAF), both nucleoside reverse transcriptase inhibitors (NRTIs), is a recommended initial ART regimen for most people with HIV in the United States. B/F/TAF is an oral, once-daily fixed-dose combination (FDC) that provides a potent and well-tolerated regimen for the treatment of HIV-1 infection in people, including those with some pre-existing resistance and subpopulations that are underrepresented in clinical trials, including Black, Hispanic, and Latine PWH, PWH ≥65 years old, and pregnant adults.

The rapid restart nature of this study involves the concurrent initiation of screening, baseline assessments, and administration of B/F/TAF on the same day. B/F/TAF is the only guideline-recommended single tablet regimen (STR) suitable for rapid restart, as it can be prescribed without prior knowledge of baseline laboratory parameters, including viral load, hepatitis B virus (HBV) status, or baseline genotypic resistance testing. This means the study treatment commences without baseline test results, provided the participant fulfills all eligibility criteria.

There will be two Cohorts of participants within this study: Cohort 1 will include viremic participants (defined by HIV-1 RNA ≥50 copies/mL) at baseline and Cohort 2 will include virologically suppressed participants (defined by HIV-1 RNA \<50 copies/mL) at baseline. The study will aim to recruit 125 participants into Cohort 1 while simultaneously recruiting into Cohort 2 (it is assumed approx. 15-75 participants). The ratio of participants in Cohort 1 and Cohort 2 will be monitored during enrollment. Adherence and drop-out rates will be closely monitored throughout the study to mitigate the risk of insufficient sample sizes to power the planned analyses. Each participant's total study participation duration will be up to 48 weeks for data collection. Participants will be followed prospectively for 48 weeks in Cohort 1 and for 24 weeks in Cohort 2. Optional, semi-structured interviews will be conducted for a subset of participants in Cohorts 1 and 2 via teleconference at week 4 and week 24 after baseline screening and treatment reinitiation. While sample size will be informed by theoretical saturation, \~30 participants (15 per Cohort) is estimated to be sufficient.

Achieving viral suppression (defined as HIV-1 RNA \<50 copies/mL) is the main goal of ART therapy for PWH who are viremic, and the primary objective of this study. It has been associated with improvements in CD4 cell counts, prevention of HIV drug resistance, AIDS- and non-AIDS-related events, and decreased transmission to sexual partners of PWH. Secondary outcomes include safety, resistance, persistence and adherence, and a range of patient-reported outcomes to understand patient experiences of ART.

02

Conditions studied

  • HIV -1 Infection
  • HIV (Human Immunodeficiency Virus)
  • HIV
  • HIV 1 Infection

Browse trials for

Keywords

  • HIV-1
  • HIV Infections
  • Bictegravir
  • Emtricitabine
  • Tenofovir Alafenamide
  • Antiretroviral Therapy
  • Antiretroviral Therapy, Highly Active
  • Treatment Interruption
  • Virologically Suppressed
  • Treatment-Experienced
  • Returning to Care
  • Phase 4
  • B/F/TAF
  • B/F/TAF; bictegravir, emtricitabine, tenofovir alafenamide, drug combination
  • Rapid Restart
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 200 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

CAN Community Health is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age at the time of signing the form (ICF)
  • Diagnosis of -1 confirmed by any positive HIV 4th generation test or detectable HIV-1 RNA level in >6 months
  • Previously received ART for ≥30 consecutive days, as self-reported
  • No ART dose received for ≥12 weeks prior to provision of informed consent, by any route of administration (i.e., injection or oral), as self-reported
  • Returning to care with an interest to restart ART therapy
  • Body weight ≥55.12lbs (25 kg)
  • Signed ICF as described in the protocol which includes compliance with the requirements and restrictions listed in ICF and study protocol

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of -2 infection
  • Known or suspected history of severe hepatic impairment ( Class C)
  • Known or suspected history of severe renal impairment (estimated [eCrCl] \<30 mL/min)
  • Concomitant medication that is with B/F/TAF
  • Known or suspected resistance to BIC (resistance-associated mutations [RAMs] include: G118R, Y143C/H/R, Q148H/K/R, N155H/S, or R263K in the integrase gene)
  • Known/suspected resistance to tenofovir (TFV) (RAMs include: K65R/E/N, or K70E)
  • Known/suspected history of 3 or more thymidine analog mutation (TAMs) (M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E/N/R), T69-insertions, or K65R/E/N in reverse transcriptase (RT)
  • History of B/F/TAF intolerance
  • Unable to swallow whole tablets or swallow tablets cut into halves
  • Unable to communicate in either English or Spanish
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Open-label B/F/TAF

    All participants receive open-label B/F/TAF. Treatment duration is determined by baseline viral load: viremic participants (defined by HIV-1 RNA ≥50 copies/mL) at baseline will receive 48 weeks of B/F/TAF; virologically suppressed participants (defined by HIV-1 RNA \<50 copies/mL) at baseline will receive 24 weeks of B/F/TAF.

    Drug: Bictegravir, emtricitabine, and tenofovir alafenamide

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants in Cohort 1 with plasma HIV-1 RNA <50 copies/mL

    Percentage of all participants who have plasma HIV-1 RNA Viral Load \<50 c/mL at W24 using FDA snapshot analysis, which defines a participant's virologic response status using only the viral load at the predefined timepoint within a certain window of time, along with study drug discontinuation

    Time frame: Week 24

  2. Percentage of participants in Cohort 2 with plasma HIV-1 RNA ≥50 copies/mL

    Percentage of all participants who have plasma HIV-1 RNA Viral Load ≥50 c/mL at W24 using FDA snapshot analysis, which defines a participant's virologic response status using only the viral load at the predefined timepoint within a certain window of time, along with study drug discontinuation

    Time frame: Week 24

Secondary outcomes

  1. Percentage of participants with plasma HIV-1 RNA <50 copies/mL

    Percentage of participants with HIV-1 RNA \<50 copies/mL assessed at Weeks 12, 24, and 48, using FDA snapshot analysis and missing values excluded

    Time frame: 48 weeks

  2. Percentage of participants with plasma HIV-1 RNA <200 copies/mL

    Percentage of participants with HIV-1 RNA \<200 copies/mL assessed at Weeks 12, 24, and 48, using FDA snapshot analysis and missing values excluded

    Time frame: 48 weeks

  3. Percentage of participants meeting protocol-defined virologic failure (PDVF) criteria in Cohort 1

    Percentage of participants meeting PDVF criteria through Weeks 24 and 48. For Cohort 1, PDVF will be defined as Suboptimal Virologic Response, in which HIV-1 RNA ≥50 copies/mL and less than 1 log10 HIV-1 RNA reduction from Day 1 at the W12 visit, or Virologic Rebound, in which at any timepoint after achieving HIV-1 RNA \<50 copies/mL, a subsequent HIV-1 RNA measurement is noted to be ≥50 copies/mL, which is then confirmed at the following scheduled or unscheduled visit

    Time frame: 48 weeks

  4. Percentage of participants meeting PDVF criteria in Cohort 2

    Percentage of participants meeting PDVF criteria through Weeks 24 and 48. For Cohort 2, PDVF will be defined as Confirmed Virologic Rebound, in which at any visit after Day 1, a rebound in HIV-1 RNA to ≥50 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit, or any participant with HIV-1 RNA ≥50 copies/mL at the last on-treatment study visit (including E/D, lost to follow-up, or study endpoints)

    Time frame: 24 weeks

  5. Absolute and change from baseline in log10 HIV-1 RNA viral load of participants

    Absolute and change from baseline in log10 HIV-1 RNA viral load at Weeks 12, 24, and 48

    Time frame: 48 weeks

  6. Absolute and change from baseline CD4 T-cell count of participants

    Absolute and change from baseline CD4 T-cell count at Weeks 12, 24, and 48. The CD4 T-cell count will be determined using the participant's blood sample. This test serves as a marker of immune system integrity and is used to evaluate immune suppression and disease progression, and monitor B/F/TAF efficacy

    Time frame: 48 weeks

  7. Percentage of participants discontinuing due to adverse events (AEs) or intolerability

    Percentage of patients discontinuing study treatment due to AEs or other intolerability through Weeks 24 and 48

    Time frame: 48 weeks

  8. Percentage of participants experiencing treatment-emergent Grade 3-4 laboratory abnormalities

    Incidence of new Grade 3-4 lab abnormalities through Weeks 24 and 48

    Time frame: 48 weeks

  9. Percentage of participants experiencing treatment-emergent Grade 3-4 drug-related adverse events

    Incidence of Grade 3-4 adverse events considered drug-related through Weeks 24 and 48

    Time frame: 48 weeks

  10. Percentage of Participants experiencing Serious Adverse Events (SAEs)

    Incidence of SAEs through Weeks 24 and 48. All SAEs will be collected from the date of the first dose of the study drug until the end of on-study treatment + 30 days

    Time frame: 48 weeks

  11. Baseline resistance to B/F/TAF

    Proportion of participants with pre-existing genotypic or phenotypic resistance to any component of B/F/TAF at study entry

    Time frame: 4 weeks

  12. Treatment-emergent resistance in PDVF participants in Cohort 1

    Proportion of participants with PDVF who develop treatment-emergent genotypic or phenotypic resistance to any component of B/F/TAF. For Cohort 1, PDVF will be defined as Suboptimal Virologic Response, in which HIV-1 RNA ≥50 copies/mL and less than 1 log10 HIV-1 RNA reduction from Day 1 at the W12 visit, or Virologic Rebound, in which at any timepoint after achieving HIV-1 RNA \<50 copies/mL, a subsequent HIV-1 RNA measurement is noted to be ≥50 copies/mL, which is then confirmed at the following scheduled or unscheduled visit

    Time frame: 48 weeks

  13. Treatment-emergent resistance in PDVF participants in Cohort 2

    Proportion of participants with PDVF who develop treatment-emergent genotypic or phenotypic resistance to any component of B/F/TAF. For Cohort 2, PDVF will be defined as Confirmed Virologic Rebound, in which at any visit after Day 1, a rebound in HIV-1 RNA to ≥50 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit, or any participant with HIV-1 RNA ≥50 copies/mL at the last on-treatment study visit (including E/D, lost to follow-up, or study endpoints)

    Time frame: 24 weeks

  14. Total satisfaction score on the HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs)

    Total score at Weeks 4, 24, and 48 on the HIVTSQs on a scale of 0 (very dissatisfied) to 6 (very satisfied)

    Time frame: 48 weeks

  15. Change from Week 4 on the Total HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) score

    Change in total HIVTSQ satisfaction score from Week 4 to Weeks 24 and 48 on a scale of 0 (very dissatisfied) to 6 (very satisfied)

    Time frame: 48 weeks

  16. Total and change from baseline in the symptom distress score on the HIV-Symptom Index (HIV-SI)

    Total score and change from baseline at Weeks 4, 24, and 48 on the HIV-SI on a scale of 0 ("I do not have this symptom") to 4 ("It bothers me a lot")

    Time frame: 48 weeks

  17. Health-related quality of life by EuroQol 5-Dimension 5-Level (EQ-5D-5L) total score and change from baseline

    Total EQ-5D-5L score and change from baseline at Weeks 4, 24, and 48 with a scale ranging from 0 (the worst health you can imagine) to 100 (the best health you can imagine)

    Time frame: Week 4

  18. Reasons for prior ART discontinuation and current reinitiation

    Participant-reported reasons for previous ART discontinuation and for reinitiation at study entry

    Time frame: Baseline

  19. Proportion of participants lost to follow-up

    Participants with no study contact through Week 48

    Time frame: Week 48

  20. Proportion of participants on study drug with documented clinic visit

    Participants taking study drug at Week 48 who have a clinic visit within 90 days after their post-treatment safety follow-up visit (Week 48 + 30 days)

    Time frame: Week 48

  21. Adherence to B/F/TAF by pill count or dried blood spot (DBS)

    Adherence rate as measured by pill counts or DBS at scheduled and/or unscheduled visits through Week 48

    Time frame: Week 48

  22. Participant experiences returning to care after HIV treatment interruption

    Semi-structured qualitative interviews will be conducted at Weeks 4 and 24 to investigate the experience of PWH who are returning to care after interrupting treatment, including barriers to initial retention in care and reasons for disengagement, motivators for re-engagement with care, as well as barriers to this process, perceptions about future risk of disengagement with care following re-engagement, and impact of restarting treatment on first visit with B/F/TAF

    Time frame: Week 24

07

Study locations

11 of 11 sites recruiting
  • CAN Community Health
    Clearwater, Florida 33765, United States
    Recruiting
  • Midway Specialty Care Center
    Ft. Pierce, Florida 34982, United States
    Recruiting
    • Hector Bolivar, MD · Contactdrbolivar@midwaycare.org · 561-249-2279
    • Jenn L Kuretski, DNP, APRN, NP-C,AAHIVS · ContactJkuretski@midwaycare.org · 772-464-9746
    • Moti Ramgopal, MD · Sub investigator
    • Angela Trodglen, APRN · Sub investigator
  • CAN Community Health
    Jacksonville, Florida 32207, United States
    Recruiting
  • CAN Community Health
    Orlando, Florida 32804, United States
    Recruiting
  • Midway Specialty Care Center
    Orlando, Florida 32819, United States
    Recruiting
    • Hector Bolivar, MD · Contactdrbolivar@midwaycare.org · 561-249-2279
    • Jenn L Kuretski, DNP, APRN, NP-C, AAHIVS · ContactJkuretski@midwaycare.org · 407-745-1171
    • Emmanuelle Allseits, MD · Sub investigator
    • Aylin Perez, PA · Sub investigator
  • CAN Community Health
    Sarasota, Florida 34237, United States
    Recruiting
  • CAN Community Health
    Tampa, Florida 33602, United States
    Recruiting
  • Midway Specialty Care Center
    Temple Terrace, Florida 33617, United States
    Recruiting
  • Midway Specialty Care Center
    West Palm Beach, Florida 33409, United States
    Recruiting
  • Midway Specialty Care Center
    Wilton Manors, Florida 33334, United States
    Recruiting
  • CAN Community Health
    Las Vegas, Nevada 89104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) from this study will not be made available to other researchers. This decision is based on considerations related to the vulnerability of the study population and the need to uphold the highest standards of data protection and confidentiality. Given that participants are living with HIV-1, which is a condition associated with significant social, legal, and personal sensitivities, sharing IPD could increase the risk of inadvertent disclosure of sensitive personal information. Ensuring the privacy and protection of identities and health data of participants is essential; therefore, we have decided not to make IPD available for other researchers' use.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 64 non-industry phase 4 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 49. This study's planned 12 months is below that.

Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 22 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Jun 17, 2027
CompletionEst.
Jun 17, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • CAN Community Health · Sarasota, United States
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added
    Show site
    • CAN Community Health · Sarasota, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07476339
Lead sponsor
CAN Community Health
Collaborators
Gilead Sciences, Midway Specialty Care Center, Costello Medical Inc.
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Jun 17, 2026
Primary completion
Jun 17, 2027 (estimated)
Completion
Jun 17, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Prerak Shukla, MD
Contact
pshukla@cancommunityhealth.org
941-366-0134 ext. 11102
Miranda Townsend
Contact
biktarvy.rapidrestartstudy@costellomedical.com
+44 7709-514-696
Jessica Altamirano, MD
principal investigator · CAN Community Health
Hector Bolivar, MD
principal investigator · Midway Specialty Care Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion